Zentiva: Expanding in the CEE through M&A
Executive Summary
The formation of Zentiva through the merger of Léciva and Slovakofarma-the leading pharmaceutical players in the Czech and Slovak markets respectively-propels the merged entity into the top ranks of the CEE pharmaceutical industry and gives the company a firm base upon which to expand internationally. Yet unlike the majority of its peers who are looking to the West to drive future growth, Zentiva is looking East. The plan: to tap into the rapidly growing and less crowded CEE markets and lead the consolidation of the industry across the region.
You may also be interested in...
Eastern Europe: The Local Advantage
As the Eastern European and CIS markets expand, in some cases accelerated by EU enlargement, firms like Menarini--which in 1992 bought a strong presence in the area through its acquisition of Berlin-Chemie--are set to benefit from increasing in-licensing opportunities and growing sales. Local expertise is paramount in these markets: they may represent biggest growth opportunity in Europe, but most are still complex bureaucratically and politically, and protectionism remains rife in many states.
Eastern Europe: The Local Advantage
As the Eastern European and CIS markets expand, in some cases accelerated by EU enlargement, firms like Menarini--which in 1992 bought a strong presence in the area through its acquisition of Berlin-Chemie--are set to benefit from increasing in-licensing opportunities and growing sales. Local expertise is paramount in these markets: they may represent biggest growth opportunity in Europe, but most are still complex bureaucratically and politically, and protectionism remains rife in many states.
Pliva: Europe is Not Enough
Buying Sobel Holdings makes Croatia's Pliva one of the first eastern European companies to buy into the US market. It's doing so cleverly, leveraging future revenues from its biggest product, azithromycin, to fund the deal, and executing it through a tax-efficient Hungarian subsidiary.